

Introduction

Interferons (IFNs) are a group of cytokines released by host cells in response to pathogens such as viruses, bacteria, or tumors. There are three classes of Interferons: Type I, Type II, and Type III. IFN- β belongs to Type I IFNs and includes 2 subtypes: IFN- β -a1 and IFN- β b1. IFN- β is used to treat Multiple Sclerosis¹.

Four trademark compounds (Rebif[®], Avonex[®], Betaseron[®], and Extavia[®]) were independently validated using a commercial ELISA kit² over a range of 5-200 pg/mL. Assay parameters were evaluated and optimized to improve the performance for the individual compounds

Materials and Methods

Specific reagents used in the assay and procedure are summarized in Table 1. The assay quantitates Human (IFN- β) in serum by sandwich enzyme linked immunosorbent assay (ELISA) and has been developed to measure low/basal levels of INF- β . The Interferon binds to plates coated with capture antibody and the detection is accomplished using a biotinylated secondary antibody followed by streptavidin conjugated to horseradish peroxidase (HRP). Tetramethybenzidine (TMB) is the substrate. Prior to preparing the standards and QCs of the fortified solutions in human serum, it was necessary to screen the matrix in order to identify the matrices with below lower limit of quantitation (BQ) levels of endogenous analyte





Figure 1. ELISA assay design

		96-well pla
Reagent	standards	Quality controls
Diluted Antibody (µL)	50	50
Sample buffer (µL)	50	50
Sample (µL)	50	50
Cover plate and place on a pla	ate shaker set a	at 450 rpm
Wash plate	3x with wash b	ouffer
Diluted HRP (µL)		100
Cover plate and place on a plate	e shaker set at	450 rpm fo
Wash plate	4x with wash b	ouffer
TMB Substrate (µL)		100
Cover plate and incubate at room t	emperature for	30 minutes
$1NH_2SO_4$ stop solution		100
Read the plate using	absorance rea	der at 450 i
Table 1. Assay procedure		

© 2012. inVentiv Health. All rights reserved.

Optimization and Validation of an ELISA kit for the Quantification of Four Interferon-Beta (IFN-ß) Marketed Compounds in Human Serum K. Abuarjah, E. Gonzalez, A. Mancino, K. O'Toole, H. Desai, C. Beaver



Results

The validation parameters of accuracy, precision, robustness, freeze-thaw stability, long-term stability, and bench-top stability were evaluated for each compound. The intra-assay and inter-assay (pooled) precision (%CV) and accuracy (%RE) for each validation sample concentration was $\leq 20\%$ ($\leq 25\%$ for LLOQ and ULOQ) for the four compounds. The inter-assay total error (|%CV| + |%RE|) was < 30% (< 40% for LLOQ).




Figure 2. Representative Calibration Curves for the four IFN- β

Compound	Statistic			Nominal Concentration (pg/mL)				
		LLOQ	QCL	QCM	QCH	ULOQ		
		5.000	15.00	60.00	150.0	200.0		
	n	36	36	36	36	36		
Pabif®	Mean Bias (%RE)	-15.5	-3.6	-4.9	-4.8	-8.7		
Rebif®	Interbatch (%CV)	20.5	9.4	6.9	4.0	5.8		
	Mean + Interbatch	36.064	12.989	11.822	8.772	14.504		
	n	36	36	36	36	36		
Avonex®	Mean Bias (%RE)	3.5	1.8	2.6	6.7	7.1		
Avonex®	Interbatch (%CV)	14.5	7.6	8.8	9.3	7.8		
	Mean + Interbatch	18.019	9.318	11.396	16.039	14.869		
	n	36	34	35	36	36		
Betaseron®	Mean Bias (%RE)	-1.8	0.3	0.5	3.7	3.9		
Delaseron	Interbatch (%CV)	7.1	5.4	4.9	3.7	7.8		
	Mean + Interbatch	8.879	5.681	5.425	7.376	11.716		
	n	36	36	36	36	35		
Extovio®	Mean Bias (%RE)	-10.0	-8.2	-10.1	-9.5	-8.9		
Extavia®	Interbatch (%CV)	11.1	5.3	7.5	6.4	3.5		
	Mean + Interbatch	21.168	13.528	17.567	15.887	12.365		

Table 2. Total Error for Precision and Accuracy

Sample	Unspiked Matrix	Spiked matrix at the QCL concentration (15.0 pg/mL)			
		Rebif	Avonex	Betaseron	Extavia
		%RE	%RE	%RE	%RE
1	<lloq< td=""><td>-2.00</td><td>-4.00</td><td>-11.3</td><td>-18.0</td></lloq<>	-2.00	-4.00	-11.3	-18.0
2	<lloq< td=""><td>8.00</td><td>9.33</td><td>5.33</td><td>2.67</td></lloq<>	8.00	9.33	5.33	2.67
3	<lloq< td=""><td>12.0</td><td>-6.67</td><td>13.3</td><td>14.0</td></lloq<>	12.0	-6.67	13.3	14.0
4	<lloq< td=""><td>-17.3</td><td>-5.33</td><td>17.3</td><td>10.7</td></lloq<>	-17.3	-5.33	17.3	10.7
5	<lloq< td=""><td>-31.3*</td><td>16.7</td><td>NC</td><td>-2.00</td></lloq<>	-31.3*	16.7	NC	-2.00
6	<lloq< td=""><td>12.7</td><td>-12.0</td><td>-10.0</td><td>-13.3</td></lloq<>	12.7	-12.0	-10.0	-13.3
7	<lloq< td=""><td>-50.7*</td><td>3.33</td><td>6.67</td><td>14.0</td></lloq<>	-50.7*	3.33	6.67	14.0
8	<lloq< td=""><td>5.33</td><td>10.0</td><td>-37.9*</td><td>-32.0*</td></lloq<>	5.33	10.0	-37.9*	-32.0*
9	<lloq< td=""><td>9.33</td><td>-25.3*</td><td>-5.33</td><td>-4.00</td></lloq<>	9.33	-25.3*	-5.33	-4.00
10	<lloq< td=""><td>11.3</td><td>-38.9*</td><td>13.3</td><td>18.7</td></lloq<>	11.3	-38.9*	13.3	18.7
LLOQ = 5.00	pg/mL				
NC = not calc	ulated				

* = Mean value outside acceptance criteria: RE ± 20% of nominal **Table 3.** Selectivity evaluation of the four IFN- β

	140 ₇
	120 -
g/ml	100 -
Concentration (pg/mL)	80 -
atio	60 -
entr	40 -
Conc	20 -
Ŭ	o +
	0.00

Figure 3. Dilution linearity of Betaseron

(pg/mL)				
Nominal	Concentration	%RE		
150	128	-14.7		
75.0	66.4	-11.5		
30.0	32.9	9.67		
15.0	18.7	24.7		
9.00	12.2	35.6		
Dilution of sample prepared from high stock was shown to be linear down				
to 30.0 pg/mL which represents 83,333 fold dilution.				

Table 4. Dilution linearity of Betaseron

	Outcome				
Validation Experiment	Rebif [®]	Avonex®	Betaseron®	Extavia®	
Short Term Stability (Bench)	4 Hours	5 Hours	4 Hours	4 Hours	
Short Term Stability (4°C)	24 Hours	48 Hours	24 Hours	4 Hours	
Freeze Thaw Stability (-80°C)	4 Cycles	4 Cycles	2 Cycles	3 Cycles	
Selectivity	No interference observed	No interference observed	No interference observed	No interference observed	
Hemolysis	No hemolysis effect observed	No hemolysis effect observed	No hemolysis effect observed	No hemolysis effect observed	
Dilution (fold)	10	10	83,333	100	
Long-Term Freezer Stability (-80°C)	153 Days	70 Days	61 Days	59 Days	

Four sensitive assays for the detection of Rebif[®], Avonex[®], Betaseron[®] and Extavia[®] were developed, optimized, and validated over a range of 5-200 pg/mL. The methods were reliable and robust, and considered suitable for the analyses of pharmacokinetic studies in human serum.

Literature cited

- Sep:8(9):1435-47.
- (Product#41415-1).

>> TRANSFORMING PROMISING IDEAS INTO COMMERCIAL REALITY




Table 5. Validation summary of the four IFN- β

Conclusions

. Weinstock-Guttman B, Ramanathan M, Zivadinov R. Interferon-beta treatment for relapsing multiple sclerosis. Expert Opin Biol Ther. 2008

2. PBL interferon Source. Verikine-HS[™] Human INF-β Serum Elisa Kit

inVentiv Health clinical